CMPS is trading 5.8% up at $14.37 following a fresh wave of bullish analyst commentary and growing optimism surrounding its Phase 3 COMP360 depression program.
- Investors are reacting to multiple recent price target hikes and strong consensus buy ratings across the board.
- Market sentiment is bolstered by expectations for favorable Phase 3 data and a clear NDA filing timeline that could unlock significant upside if results are positive.